Small molecule · Modulator of sigma-1 receptor (SIGMAR1) and muscarinic acetylcholine receptor M1 (CHRM1) · developed by Anavex Life Sciences
ANAVEX3-71 is an oral small molecule that acts as an agonist at the sigma-1 receptor (SIGMAR1) and as a positive allosteric modulator with agonistic effects at the M1 muscarinic acetylcholine receptor. It is being studied in schizophrenia, including its positive, negative and cognitive symptom domains.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06245213 | Phase 2 | Schizophrenia | Active not recruiting | AVXL |
| NCT04442945 | Phase 1 | Healthy | Completed | AVXL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
SchizophreniaHealthy
Updated Nov 8, 2026. Something wrong or missing? Report it on the AVXL page.
See AVXL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVXL catalysts and pipeline →